Skip to main content
. 2025 Mar 3;33(2):e004358. doi: 10.1136/ejhpharm-2024-004358

Table 3. Results of turbidity changes in solutions.

Drug Turbidity/NTU
AVG±SD (change)
0 hour 1 hour 2 hour 4 hour
Tigecycline(1 mg/mL)A1 0.103±0.003 0.113±0.004 (0.010) 0.124±0.005 (0.021) 0.116±0.002 (0.013)
Tigecycline(0.5 mg/mL)A2 0.082±0.008 0.097±0.015 (0.015) 0.108±0.001 (0.026) 0.104±0.004 (0.022)
Metronidazole and sodium chloride injectionB 0.132±0.002 0.115±0.007 (−0.017) 0.101±0.004 (−0.031) 0.092±0.003 (−0.040)
MeropenemC 0.104±0.008 0.09±0.003 (−0.014) 0.096±0.003 (−0.008) 0.092±0.003 (−0.012)
Imipenem and cilastatinD 0.174±0.005 0.168±0.002 (−0.006) 0.169±0.001 (−0.005) 0.151±0.002 (−0.023)
Fosfomycin sodiumE 0.199±0.006 0.185±0.006 (−0.014) 0.162±0.006 (−0.037) 0.152±0.003 (−0.047)
AztreonamF 0.650±0.002 0.670±0.016 (0.020) 0.676±0.003 (0.026) 0.635±0.003 (−0.015)
VancomycinG 0.186±0.002 0.181±0.003 (−0.005) 0.201±0.004 (0.015) 0.197±0.004 (0.011)
CAZ-AVI H 0.074±0.009 0.079±0.003 (0.005) 0.079±0.008 (0.005) 0.078±0.007 (0.004)
Calcium chloride with composite potassium hydrogen phosphateI 26.390±0.181 102.23±5.261 (75.840)

A1-G: the combinations of CAZ-AVI with selected drugs separately; H: negative control, 25 mg/ml CAZ-AVI in NS; I: positive control, calcium chloride with composite potassium in NS; J: positive control, 10 μm latex particles reference material; K: positive control, 25 μm particle count reference material; N: Tyndall negative; P: Tyndall positive.